TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03242473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Management
Description: The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Management
Description: The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
Study: NCT03870230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT
Study: NCT01803672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health talk and adventure-based training
Description: To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
Study: NCT01051960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan 5mg or 10mg once daily
Study: NCT03173118

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ultrasound elastography
Description: Endoscopic ultrasound elastography performed on both groups of patients as per routine
Study: NCT01168128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Change Strategy
Description: e.g. Education, decision support tools
Study: NCT01545167

Intervention type: GENETIC
Intervention: blood sampling
Description: blood samples obtained to extract biomarkers and dna for analysis, questionnaires

Intervention type: GENETIC
Intervention: blood sampling
Description: blood samples obtained to extract biomarkers and dna for analysis, questionnaires
Study: NCT03775616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive financial navigation program intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01958437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
Study: NCT03146806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: 10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse.
Study: NCT03373877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
Study: NCT04232085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Preparative regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Total Body Irradiation
Description: Preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: GVHD prophylaxis
Study: NCT03870230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device
Study: NCT04232085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: GVHD prophylaxis
Study: NCT01484171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: idarubicin 10-12 mg/m2 for three days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
Study: NCT02675426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral
Study: NCT04232085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: GVHD prophylaxis
Study: NCT03870230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal vessel diameters and oxygen saturation will be measured with the DVA device
Study: NCT02675426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study: NCT04296461

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Welgenaleucel
Description: Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
Study: NCT03625817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mountainous setting
Description: The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having \>800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
Study: NCT02846987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Study: NCT03735966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus trastuzumab and docetaxel and carboplatin
Description: pyrotinib: 320mg orally daily，6cycles; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6cycles; docetaxel:after the biological window, 100mg/m2 for a total of 6 cycles carboplatin:d1 ，AUC 6 iv 3-weekly for a total of 6 cycles
Study: NCT03613857

Intervention type: DRUG
Intervention: Clopidogrel
Description: 8 tablets 75 mg clopidogrel loading dose before PCI

Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: 2 tablets 90 mg brilique before PCI
Study: NCT03070522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral prednisone for 7 days during pulmonary exacerbation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT03379025

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic cigarette
Description: electronic cigarette and cartridge refills (also known as pods)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: electronic cigarette and cartridge refills (also known as pods)
Study: NCT02053948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pursestring Wound Closure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gunsight Skin Incision and Closure Technique
Study: NCT04225208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AZD4205, single 50 mg oral dose administrated on day 1
Description: Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Study: NCT03002181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: 70 minute education session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: 70 minute education session.
Study: NCT03850119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat injection
Description: Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
Study: NCT03894449

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
Study: NCT04232085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: GVHD prophylaxis
Study: NCT03894449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prebiotic + Iron Forificant
Description: A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
Study: NCT03859323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP681
Description: Participants will receive SC injection of SHP681 in the abdomen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injection of placebo matched to SHP681 in the abdomen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
Study: NCT04054583

Intervention type: OTHER
Intervention: Renovation of long-term residential care living spaces
Description: Living spaces of the long term care facility will be renovated.

Intervention type: OTHER
Intervention: Renovation of long-term residential care living spaces
Description: Living spaces of the long term care facility will be renovated.

Intervention type: OTHER
Intervention: Renovation of long-term residential care living spaces
Description: Living spaces of the long term care facility will be renovated.
Study: NCT02648698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
Study: NCT04458584

Intervention type: PROCEDURE
Intervention: Trapeziectomy with ligament reconstruction (I; LRTI)
Description: Thumb basal joint arthroplasty (surgical) using Trapeziectomy with ligament reconstruction (I; LRTI)

Intervention type: PROCEDURE
Intervention: Trapeziectomy with suture suspensionplasty (II; SS)
Description: Thumb basal joint arthroplasty (surgical) using Trapeziectomy with suture suspension-lastly (II; SS)

Intervention type: PROCEDURE
Intervention: Arthroscopic Trapeziectomy (III; AT)
Description: Thumb basal joint arthroplasty (surgical) using Arthroscopic Trapeziectomy (III; AT)
Study: NCT02295111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EA treatment
Description: Electro acupuncture and traditional Chinese Medicine Health consult

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCM health consult
Description: Traditional Chinese Medicine Health Consult without needling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard NHS care
Study: NCT02081300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate, LPCN 1021

Intervention type: DRUG
Group type: OTHER
Intervention: Topical testosterone gel 1.62 %
Study: NCT03021382

Intervention type: OTHER
Intervention: data collection, non-intervention

Intervention type: OTHER
Intervention: data collection, non-intervention
Study: NCT02337647

Intervention type: OTHER
Group type: OTHER
Intervention: DCDC App
Description: The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
Study: NCT03380442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin ingested orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine (Ketalar)
Description: Ketamine administered intranasally
Study: NCT00354705

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two questionnaires taking 30 minutes to complete.
Study: NCT03956017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinone
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
Study: NCT05363033

Intervention type: DEVICE
Intervention: sarcopenia nursing guidance mobile application was developed
Description: The application enhanced participants' sarcopenia-related knowledge and awareness regarding self-care
Study: NCT03725982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laevo ®
Description: A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laevo ®
Description: A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
Study: NCT01883297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Re-stimulated tumor-infiltrating lymphocytes (TILs)
Description: Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
Study: NCT01682447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive Pulmonary Rehabilitation Program
Description: Fulltime pulmonary rehabilitation program. Duration: 12 weeks
Study: NCT01863368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-free saline solution eyedrops
Description: 1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preservative-free saline solution eyedrops
Description: 1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® ULTRA lubricant eyedrops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIVE® lubricating eyedrops
Study: NCT02195219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction internal fixation
Description: MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sling rest and early functional recovery
Description: Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
Study: NCT00960284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04083950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Positive Control)
Description: Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.